Hims & Hers Health (NYSE:HIMS) Given New $16.00 Price Target at Deutsche Bank Aktiengesellschaft

Hims & Hers Health (NYSE:HIMS) had its target price increased by Deutsche Bank Aktiengesellschaft from $14.00 to $16.00 in a research note published on Tuesday, Benzinga reports. The brokerage currently has a hold rating on the stock.

A number of other research analysts have also issued reports on HIMS. Seaport Res Ptn restated a buy rating on shares of Hims & Hers Health in a report on Friday, April 26th. Jefferies Financial Group restated a hold rating and set a $15.00 target price (down previously from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. Piper Sandler boosted their price target on Hims & Hers Health from $11.00 to $13.00 and gave the company a neutral rating in a report on Tuesday. Leerink Partnrs restated a market perform rating on shares of Hims & Hers Health in a report on Monday, February 26th. Finally, Truist Financial upped their target price on Hims & Hers Health from $10.00 to $13.00 and gave the company a hold rating in a research note on Tuesday, February 27th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus price target of $15.07.

Hims & Hers Health Trading Up 6.1 %

Shares of HIMS opened at $12.36 on Tuesday. The company has a 50-day moving average of $14.04 and a two-hundred day moving average of $10.35. The stock has a market cap of $2.65 billion, a P/E ratio of -112.36 and a beta of 0.97. Hims & Hers Health has a 12-month low of $5.65 and a 12-month high of $17.16.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The firm had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. Hims & Hers Health’s revenue was up 45.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.05) EPS. As a group, analysts forecast that Hims & Hers Health will post 0.11 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In other news, COO Melissa Baird sold 11,750 shares of the firm’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $12.08, for a total value of $141,940.00. Following the transaction, the chief operating officer now owns 538,932 shares of the company’s stock, valued at approximately $6,510,298.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, COO Melissa Baird sold 11,750 shares of the stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $12.08, for a total value of $141,940.00. Following the completion of the sale, the chief operating officer now owns 538,932 shares in the company, valued at $6,510,298.56. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Andrew Dudum sold 97,208 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $9.58, for a total value of $931,252.64. Following the transaction, the chief executive officer now directly owns 51,653 shares in the company, valued at $494,835.74. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 736,191 shares of company stock worth $9,733,700. Company insiders own 31.63% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors have recently added to or reduced their stakes in the company. FNY Investment Advisers LLC acquired a new stake in shares of Hims & Hers Health during the fourth quarter valued at about $48,000. Belpointe Asset Management LLC acquired a new stake in Hims & Hers Health during the 3rd quarter valued at approximately $76,000. EMC Capital Management increased its holdings in Hims & Hers Health by 80.0% during the 3rd quarter. EMC Capital Management now owns 12,000 shares of the company’s stock worth $79,000 after purchasing an additional 5,332 shares during the last quarter. Certuity LLC acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at approximately $109,000. Finally, Corton Capital Inc. purchased a new position in shares of Hims & Hers Health during the 3rd quarter valued at approximately $122,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.